Journal profile · Multiple
Pharmacoeconomics-Open
ISSN 2509-4262 · eISSN 2509-4254 · Adis, Springer Healthcare · United Kingdom · 6 issues per year
Pharmacoeconomics-Open: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.4 (journal website); fully open access; APC about USD 4,090; median 199 days to acceptance (55 articles, last 24 months); 77 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Pharmacoeconomics-Open is published by Adis, Springer Healthcare and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Health Systems, Economic Evaluations, Quality of Life, Economic and Financial Impacts of Cancer and Pharmaceutical Economics and Policy, together about 48.7% of its articles. Its main subfields are Economics and Econometrics. (generated from OpenAlex topic counts and CAS ranking data)
PharmacoEconomics - Open focuses on applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. The journal includes, but is not limited to, the following research areas: Economic analysis of healthcare interventions Health outcomes research Cost-of-illness studies Quality-of-life studies The journal also publishes study protocols for health economics and outcomes research and reviews.
From the journal's Aims & Scope
Research area (LetPub): Multiple
Editorial board by country: 2 in mainland China (about 4%); most named United States 11, United Kingdom 9, Australia 6, Canada 5, Netherlands 4 (52 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance29.4%
- Economic and Financial Impacts of CancerEconomics, Econometrics and Finance12.7%
- Pharmaceutical Economics and PolicyEconomics, Econometrics and Finance6.7%
- Economic and Environmental ValuationEconomics, Econometrics and Finance4.7%
- Multiple Sclerosis Research StudiesMedicine3.3%
- Healthcare Policy and ManagementEconomics, Econometrics and Finance3.3%
- Medication Adherence and ComplianceMedicine3.2%
- Cancer Immunotherapy and BiomarkersMedicine3.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Economics | Zone 4 |
| Minor | Health Care Sciences & Services | Zone 4 |
| Minor | Health Policy & Services | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Economics | Zone 3 |
| Minor | Health Care Sciences & Services | Zone 3 |
| Minor | Health Policy & Services | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbasePublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar, RePEc
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2.4Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.6Publisher website ·
- CiteScore 2026-06
- 4.3LetPub ·
- SJR 2026-06
- 0.86LetPub ·
- SNIP 2026-06
- 1LetPub ·
- h-index
- 39OpenAlex ·
- i10-index
- 236OpenAlex ·
- 2-year mean citedness
- 2.94OpenAlex ·
- Self-citation rate
- 4.2%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 74LetPub ·
- Articles per year (publisher)
- 2,025Publisher website ·
- Downloads per year (publisher) 2025
- 581,200Publisher website ·
Articles by year OpenAlex count · 674 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 53 | 53 | 7 |
| 2025 | 77 | 77 | 150 |
| 2024 | 88 | 88 | 485 |
| 2023 | 77 | 77 | 599 |
| 2022 | 67 | 67 | 749 |
| 2021 | 71 | 71 | 1,054 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
199 daysMedian, submission to acceptance · P25–P75 152 days – 249 days
- Acceptance to online
- median 25 days (95 articles)
- Submission to online
- median 231 days
- Sample
- 55 articles with submission and acceptance dates (153 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 8 weeksLetPub ·
- Submission to first decision
- 14 daysPublisher website ·
- Peer review
- Anonymous peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,090 / EUR 3,190 / GBP 2,790 | — | — | |
| LetPub | GBP 2,590 / USD 3,790 / EUR 2,990 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- 150–250 words
- Manuscript length
- ≤ 6,000 words
- Reference style
- Numbered, in order of citation
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Optional
Article types accepted17
- commentaryThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- current opinionCurrent Opinion. Word count approximately up to 3000.Length not stated
- editorialThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- editorial/commentaryEditorial/Commentary. Word count up to 1500.Length not stated
- leading articleLeading Article. Word count up to 4000.Length not stated
- letter to the editorThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- opinionThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- original articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- original researchThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- original research articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- perspectiveThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- practical applicationPractical Application. Word count up to 3000.Length not stated
- research articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- reviewThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- review articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- summary of research article (sra)Summary of Research Article (SRA): A standalone summary of a source article previously published in an Adis journal, or in a journal from another publisher.Length not stated
- systematic reviewThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship Principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
Data availability statement required for all original research Model summary
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- License & copyright Copyright
In confirming the publication of your article with open access you agree to the Creative Commons Attribution Non-Commercial License 4.0 International License Find more about the license agreement Back to top
Source ↗Publisher website ·- Open access Open access publishing
Open access under CC BY-NC 4.0 Model summary
To find out more about publishing your work Open Access in PharmacoEconomics - Open, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Adis, Springer Healthcare
- Country or region
- United Kingdom
- Language
- English
- Frequency
- 6 issues per year
- ISSN
- 2509-4262
- Electronic ISSN
- 2509-4254
- Latest issue on the website
- Volume 10, Issue 4 (July 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Pharmacoeconomics-Open
What CAS zone is Pharmacoeconomics-Open in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pharmacoeconomics-Open is in Zone 4 of Medicine, and in Zone 4 of the minor category Economics / Health Care Sciences & Services / Health Policy & Services / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Pharmacoeconomics-Open?
The journal's website gives an impact factor of 2.4 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4.3, h-index 39.
How long does peer review take at Pharmacoeconomics-Open?
Based on the dates recorded on 55 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 199 days (interquartile range 152–249 days); authors report an average review time of about 8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Pharmacoeconomics-Open?
According to the journal's author guidelines: Abstract: 150–250 words; Manuscript length: ≤ 6,000 words; Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Pharmacoeconomics-Open based?
Of the 52 board members whose country the journal's board page names, 2 (about 4%) are in mainland China; the countries named most often are United States (11), United Kingdom (9) and Australia (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Pharmacoeconomics-Open?
According to LetPub and DOAJ records, Pharmacoeconomics-Open is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Embase; that list has not been checked against each database.
Is Pharmacoeconomics-Open open access, and what is the APC?
Pharmacoeconomics-Open is a fully open-access journal. APC about USD 4,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .